Amos Panet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12108606/publications.pdf

Version: 2024-02-01

68 papers	3,016 citations	212478 28 h-index	190340 53 g-index
69	69	69	3216
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Human Nasal and Lung Tissues Infected <i>Ex Vivo</i> with SARS-CoV-2 Provide Insights into Differential Tissue-Specific and Virus-Specific Innate Immune Responses in the Upper and Lower Respiratory Tract. Journal of Virology, 2021, 95, e0013021.	1.5	47
2	Human Nasal Turbinate Tissues in Organ Culture as a Model for Human Cytomegalovirus Infection at the Mucosal Entry Site. Journal of Virology, 2020, 94, .	1.5	6
3	A Novel Tool for Nasal Polyp Investigation: An Ex vivo Organ Culture System. Israel Medical Association Journal, 2020, 22, 48-52.	0.1	O
4	Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus. Antiviral Research, 2019, 172, 104639.	1.9	22
5	Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases. Journal of Controlled Release, 2018, 291, 80-89.	4.8	27
6	Zika Virus Infects Early- and Midgestation Human Maternal Decidual Tissues, Inducing Distinct Innate Tissue Responses in the Maternal-Fetal Interface. Journal of Virology, 2017, 91, .	1.5	95
7	APOBEC3A Is Upregulated by Human Cytomegalovirus (HCMV) in the Maternal-Fetal Interface, Acting as an Innate Anti-HCMV Effector. Journal of Virology, 2017, 91, .	1.5	27
8	Zika Virus Escapes NK Cell Detection by Upregulating Major Histocompatibility Complex Class I Molecules. Journal of Virology, 2017, 91, .	1.5	55
9	Sustained secretion of antiâ€ŧumor necrosis factor α monoclonal antibody from <i>ex vivo</i> genetically engineered dermal tissue demonstrates therapeutic activity in mouse model of rheumatoid arthritis. Journal of Gene Medicine, 2017, 19, e2965.	1.4	4
10	Innate defense mechanisms against HSV-1 infection in the target tissues, skin and brain. Journal of NeuroVirology, 2016, 22, 641-649.	1.0	10
11	Preclinical and preliminary clinical evaluation of genetically transduced dermal tissue implants for the sustained secretion of erythropoietin and interferon $\hat{I}\pm$. Human Gene Therapy Clinical Development, 2015, , .	3.2	O
12	Therapeutic potential of oncolytic Newcastle disease virus a critical review. Oncolytic Virotherapy, 2015, 4, 49.	6.0	45
13	Preclinical and Preliminary Clinical Evaluation of Genetically Transduced Dermal Tissue Implants for the Sustained Secretion of Erythropoietin and Interferon \hat{l}_{\pm} . Human Gene Therapy Clinical Development, 2015, 26, 216-227.	3.2	9
14	Human cytomegalovirus induces a distinct innate immune response in the maternal–fetal interface. Virology, 2015, 485, 289-296.	1.1	29
15	Transition toward Human Cytomegalovirus Susceptibility in Early Human Embryonic Stem Cell-Derived Neural Precursors. Journal of Virology, 2015, 89, 11159-11164.	1.5	18
16	Different modes of herpes simplex virus type 1 spread in brain and skin tissues. Journal of NeuroVirology, 2014, 20, 18-27.	1.0	13
17	Models of vertical cytomegalovirus (CMV) transmission and pathogenesis. Seminars in Immunopathology, 2014, 36, 615-625.	2.8	54
18	Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity. Journal of General Virology, 2012, 93, 1664-1672.	1.3	23

#	Article	IF	Citations
19	Integrated Strategy for the Production of Therapeutic Retroviral Vectors. Human Gene Therapy, 2011, 22, 370-379.	1.4	11
20	Biopump: Autologous skin-derived micro-organ genetically engineered to provide sustained continuous secretion of therapeutic proteins. Dermatologic Therapy, 2011, 24, 489-497.	0.8	11
21	Infant lungs are preferentially infected by adenovirus and herpes simplex virus type 1 vectors: role of the tissue mesenchymal cells. Journal of Gene Medicine, 2011, 13, 101-113.	1.4	10
22	Characterization of factors that determine lentiviral vector tropism in skin tissue using an <i>ex vivo</i> model. Journal of Gene Medicine, 2011, 13, 209-220.	1.4	7
23	Modeling of Human Cytomegalovirus Maternal-Fetal Transmission in a Novel Decidual Organ Culture. Journal of Virology, 2011, 85, 13204-13213.	1.5	68
24	Restrictions that control herpes simplex virus type 1 infection in mouse brain ex vivo. Journal of General Virology, 2011 , 92 , 2383 - 2393 .	1.3	13
25	The Oncolytic Activity of Newcastle Disease Virus NDV-HUJ on Chemoresistant Primary Melanoma Cells Is Dependent on the Proapoptotic Activity of the Inhibitor of Apoptosis Protein Livin. Journal of Virology, 2010, 84, 639-646.	1.5	58
26	Herpes Simplex Virus Type 1 Preferentially Targets Human Colon Carcinoma: Role of Extracellular Matrix. Journal of Virology, 2008, 82, 999-1010.	1.5	38
27	Tropism of Lentiviral Vectors in Skin Tissue. Human Gene Therapy, 2008, 19, 255-266.	1.4	14
28	Time Frames for Neutralization during the Human Immunodeficiency Virus Type 1 Entry Phase, as Monitored in Synchronously Infected Cell Cultures. Journal of Virology, 2007, 81, 3525-3534.	1.5	17
29	Neurotropism of herpes simplex virus type 1 in brain organ cultures. Journal of General Virology, 2006, 87, 2827-2837.	1.3	49
30	Phase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme. Molecular Therapy, 2006, 13, 221-228.	3.7	329
31	Prolonged transgene expression in murine salivary glands following non-primate lentiviral vector transduction. Molecular Therapy, 2005, 12, 137-143.	3.7	14
32	Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins. Molecular Therapy, 2005, 12, 274-282.	3.7	34
33	Synchronized Infection of Cell Cultures by Magnetically Controlled Virus. Journal of Virology, 2005, 79, 622-625.	1.5	48
34	Human peripheral blood eosinophils induce angiogenesis. International Journal of Biochemistry and Cell Biology, 2005, 37, 628-636.	1.2	111
35	Transgenic Mouse with the Herpes Simplex Virus Type 1 Latency-Associated Gene: Expression and Function of the Transgene. Journal of Virology, 2003, 77, 12421-12429.	1.5	12
36	Gene Delivery by Viral Vectors in Primary Cultures of Lacrimal Gland Tissue., 2003, 44, 1529.		10

#	Article	IF	Citations
37	Viral mediated gene transfer to sprouting blood vessels during angiogenesis. Journal of Virological Methods, 2002, 105, 1-11.	1.0	8
38	Gene transfer mediated by different viral vectors following direct cannulation of mouse submandibular salivary glands. European Journal of Oral Sciences, 2002, 110, 254-260.	0.7	25
39	Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Letters, 2001, 495, 56-60.	1.3	157
40	Imaging Transgene Expression in Live Animals. Molecular Therapy, 2001, 4, 239-249.	3.7	167
41	A synthetic heparin-mimicking polyanionic compound binds to the LDL receptor-related protein and inhibits vascular smooth muscle cell proliferation. Journal of Cellular Biochemistry, 2001, 81, 114-127.	1.2	11
42	Avian Hemangioma Retrovirus Induces Cell Proliferation via the Envelope (env) Gene. Virology, 2000, 276, 161-168.	1.1	41
43	Herpes Simplex Virus Type 1 Latency-Associated Transcripts Suppress Viral Replication and Reduce Immediate-Early Gene mRNA Levels in a Neuronal Cell Line. Journal of Virology, 1998, 72, 5067-5075.	1.5	93
44	Variant mouse lymphoma cells with modified response to interferon demonstrate enhanced immunogenicity. Cancer Immunology, Immunotherapy, 1997, 44, 249-256.	2.0	5
45	Programmed Endothelial Cell Death Induced by an Avian Hemangioma Retrovirus Is Density Dependent. Virology, 1996, 223, 233-237.	1.1	14
46	Heparin-binding domain, type 1 and type 2 repeats of thrombospondin mediate its interaction with human breast cancer cells., 1996, 62, 431-442.		18
47	Expression and Splicing of the Latency-Associated Transcripts of Herpes Simplex Virus Type 1 in Neuronal and Non-Neuronal Cell Lines1. Journal of Biochemistry, 1995, 117, 1288-1297.	0.9	31
48	Apolipoprotein E: A potent inhibitor of endothelial and tumor cell proliferation. Journal of Cellular Biochemistry, 1994, 54, 299-308.	1.2	109
49	Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. Journal of Cellular Biochemistry, 1993, 53, 74-84.	1.2	153
50	Isolation and characterization of interferon-resistant variants from S49 mouse lymphoma. Experimental Cell Research, 1988, 177, 37-46.	1.2	1
51	Use of reconstituted Sendai virus envelopes for fusion-mediated microinjection of double-stranded RNA: inhibition of protein synthesis in interferon-treated cells. Biochimica Et Biophysica Acta - Biomembranes, 1986, 859, 88-94.	1.4	8
52	Production and characterization of interferon from endothelial cells. Journal of Cellular Physiology, 1985, 122, 200-204.	2.0	38
53	The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Experimental Cell Research, 1985, 161, 297-306.	1.2	90
54	Regulation of the antiviral and anticellular activities of interferon by exogenous double-stranded RNA. Molecular and Cellular Biochemistry, 1983, 52, 153-60.	1.4	12

#	Article	IF	CITATIONS
55	Activation of ribonuclease F by the two isomers (2'-5') oligoadenylate and (3'-5') oligoadenylate. FEBS Letters, 1982, 149, 47-50.	1.3	6
56	Differential inhibition of DNA polymerase and RNase H activities of the reverse transcriptase by phosphonoformate. Molecular and Cellular Biochemistry, 1982, 43, 97-103.	1.4	20
57	Effect of 2′5′-oligoadenylic acid on a mouse cell line partially resistant to interferon. Virology, 1981, 114, 567-572.	1.1	31
58	A Mouse Cell Line, which Is Unprotected by Interferon against Lytic Virus Infection, Lacks Ribonuclease F Activity. FEBS Journal, 1981, 118, 9-15.	0.2	80
59	MECHANISMS OF INTERFERON ACTION ON CELL GROWTH AND ON MURINE LEUKEMIA, VESICULAR STOMATITIS, AND ENCEPHALOMYOCARDITIS VIRUSES. , 1981, , 385-401.		0
60	Restriction of murine leukemia proviral gene expression in somatic mouse cell hybrids. Virology, 1980, 106, 197-206.	1.1	0
61	Electron microscopic evidence for splicing of Moloney murine leukemia virus RNAs. Nucleic Acids Research, 1978, 5, 3219-3230.	6.5	18
62	Binding of tRNA to Reverse Transcriptase of RNA Tumor Viruses. Journal of Virology, 1978, 26, 214-220.	1.5	71
63	Selective degradation of integrated murine leukemia proviral DNA by deoxyribonucleases. Cell, 1977, 11, 933-940.	13.5	101
64	Interaction of tryptophan tRNA and avian myeloblastosis virus reverse transcriptase: further characterization of the binding reaction. Biochemistry, 1977, 16, 3625-3632.	1.2	61
65	Ordered transcription of RNA tumor virus genomes. Journal of Molecular Biology, 1976, 106, 109-131.	2.0	194
66	The Binding of Purified Phe-tRNA and Peptidyl-tRNAPhe to Escherichia coli Ribosomes. FEBS Journal, 1971, 23, 523-527.	0.2	72
67	Reaction of Puromycin with Chemically Prepared Peptidyl Transfer RNA. FEBS Journal, 1970, 15, 215-221.	0.2	26
68	Substrate Specificity of Escherichia coli Peptidyl-Transferase. FEBS Journal, 1970, 15, 222-225.	0.2	15